Oral administration of the herbal oligonucleotide XKC-sRNA-h3 prevents angiotensin II-induced hypertension in mice

Sci China Life Sci. 2023 Oct;66(10):2370-2379. doi: 10.1007/s11427-022-2275-3. Epub 2023 Mar 17.

Abstract

Hypertension has become a growing public health concern worldwide. In fact, hypertension is commonly associated with increased morbidity and mortality. Currently, oligonucleotide drugs have proven to be promising therapeutic agents for various diseases. In the present study, we aimed to demonstrate that a herbal small RNA (sRNA), XKC-sRNA-h3 (B55710460, F221. I000082.B11), exhibits potent antihypertensive effects by targeting angiotensin-converting enzyme (ACE) in mice. When compared with captopril, oral administration of the sphingosine (d18:1)-XKC-sRNA-h3 bencaosome more effectively prevented angiotensin II-induced hypertensive cardiac damage and alleviated kidney injury in mice. Such findings indicated that XKC-sRNA-h3 may be a novel orally available ACE inhibitor type oligonucleotide drug for hypertension.

Keywords: hypertension; oligonucleotide drug; oral administration.

MeSH terms

  • Administration, Oral
  • Angiotensin II*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Blood Pressure
  • Captopril / pharmacology
  • Captopril / therapeutic use
  • Hypertension* / chemically induced
  • Hypertension* / drug therapy
  • Mice

Substances

  • Angiotensin II
  • Angiotensin-Converting Enzyme Inhibitors
  • Captopril